CDC42BPA and acute myeloid leukemia: Herein, continuing efforts to thoroughly examine the therapeutic efficacy of (5Z)-2–5-(1H-pyrrolo[2,3-b]pyridine-3-ylmethylene)-1,3-thiazol-4(5H)-one (DJ4), a ROCK and myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK) inhibitor [50], towards acute myeloid leukemia are presented.